The groundbreaking rise of Sildenafil presented a considerable prospect for the market, but its patent has ended, creating a intricate landscape. Off-brand versions have entered the arena, eroding profits and putting a strain on profit percentages . While leading healthcare companies hold a foothold in this field , the outlook seems ambiguous by fi